331061 RESULTS
COMMENT The data presented in this case report continue to support the hypothesis that the mechanism underlying ARIA closely relates to CAA and likely shares many mechanistic links with CAA-related inflammation (CAA-ri). These findings emphasize the importance of
COMMENT At Mayo Rochester we began use of lecanemab in eligible patients in late fall. It’s a positive step for our patients to have an additional treatment option to slow early Alzheimer’s disease, and it has been rewarding for our clinicians to be able to offer
COMMENT We are excited to see the work of Chou et al. suggesting a link between INPP5D and inflammasomes (Chou et al., 2023). Their findings dovetail nicely with our recent paper, which found the INPP5D in human brain has multiple transcription start sites and tw
JOB 2024-01-26 Employer Harvard Medical School and Brigham & Women’s Hospital Contact Applications should be directed to Saranna Fanning, Ph.D. (sfanning2@bwh.harvard.edu). Description A postdoctoral position is available under the mentorship of Saranna Fanning and
MUTATIONS PSEN1 73685872 GRCh37/hg19 rs1398951357 A G Exon 12 Coding Unknown, but predicted in silico to be damaging (PHRED-scaled CADD score = 20.3). Unknown. I427V Alzheimer's Disease: Uncertain SignificanceAlzheimer's Disease This variant was reported
JOB 2024-01-26 Employer The National Institute on Aging (NIA) Contact Submit your resume or CV to niajobs@mail.nih.gov attn: Zenaida Cammas. Please include ‘RWD’ and note the position of interest in the subject line. Description Chief Medical Officer - Provide guidance
JOB 2024-01-26 Employer University of Pittsburgh School of Medicine Principal Investigator Amantha Thathiah Contact Interested postdoctoral candidates should send a brief statement of research accomplishments and future interests, contact information for three reference
Ph.D. StudentSanta Barbara, United States
RESEARCH NEWS 2024-01-26 Research News Part 1 of 2. Click here for Part 2. As Alzheimer’s clinicians across the U.S. started offering a disease-modifying treatment to their patients, uptake at first was slow but is now speeding up. Six months after Eisai’s anti-amyloid antibody l
CONFERENCE 2024-12-09 00:00:00-2024-12-12 00:00:00 Cold Spring Harbor, New York 09 – 12 December 2024 View Conference Website 0
CONFERENCE 2024-12-04 00:00:00-2024-12-07 00:00:00 Cold Spring Harbor, New York 04 – 07 December 2024 View Conference Website 0
CONFERENCE 2024-09-24 00:00:00-2024-09-28 00:00:00 Cold Spring Harbor, New York 24 – 28 September 2024 View Conference Website 0
CONFERENCE 2024-09-10 00:00:00-2024-09-14 00:00:00 Cold Spring Harbor, New York 10 – 14 September 2024 View Conference Website 0
CONFERENCE 2024-08-20 00:00:00-2024-08-24 00:00:00 Cold Spring Harbor, New York 20 – 24 August 2024 View Conference Website 0
Laboratory of Proteolytic Mechanisms in Neurodegeneration (VIB-KU Leuven)Leuven, Belgium
No filters selected
